73 related articles for article (PubMed ID: 23200895)
1. PDGF α receptor is a mediator for Cisplatin-induced Met expression.
Kina S; Phonaphonh T; Liang F; Kuang H; Arasaki A; Arakaki K; Nakasone T; Sunakawa H
Eur J Pharmacol; 2013 Jan; 699(1-3):227-32. PubMed ID: 23200895
[TBL] [Abstract][Full Text] [Related]
2. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
Schultz JD; Rotunno S; Riedel F; Anders C; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Int J Oncol; 2011 Apr; 38(4):1001-12. PubMed ID: 21249316
[TBL] [Abstract][Full Text] [Related]
4. Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum.
Ma Y; Yuan RQ; Fan S; Hu C; Goldberg ID; Laterra JJ; Rosen EM
Anticancer Drugs; 2006 Aug; 17(7):733-51. PubMed ID: 16926624
[TBL] [Abstract][Full Text] [Related]
5. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
6. HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells.
Chen JT; Huang CY; Chiang YY; Chen WH; Chiou SH; Chen CY; Chow KC
Am J Respir Cell Mol Biol; 2008 May; 38(5):559-65. PubMed ID: 18096875
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
8. A novel mechanism for acquired cisplatin-resistance: suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2'-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells.
Bai T; Tanaka T; Yukawa K; Umesaki N
Int J Oncol; 2006 Feb; 28(2):497-508. PubMed ID: 16391806
[TBL] [Abstract][Full Text] [Related]
9. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
Zhang P; Gao WY; Turner S; Ducatman BS
Mol Cancer; 2003 Jan; 2():1. PubMed ID: 12537587
[TBL] [Abstract][Full Text] [Related]
10. Potential role of transforming growth factor beta1 in drug resistance of tumor cells.
Stoika R; Yakymovych M; Souchelnytskyi S; Yakymovych I
Acta Biochim Pol; 2003; 50(2):497-508. PubMed ID: 12833174
[TBL] [Abstract][Full Text] [Related]
11. HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells.
Moore AE; Greenhough A; Roberts HR; Hicks DJ; Patsos HA; Williams AC; Paraskeva C
Carcinogenesis; 2009 Oct; 30(10):1796-804. PubMed ID: 19638428
[TBL] [Abstract][Full Text] [Related]
12. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.
Hiscox S; Jordan NJ; Jiang W; Harper M; McClelland R; Smith C; Nicholson RI
Endocr Relat Cancer; 2006 Dec; 13(4):1085-99. PubMed ID: 17158755
[TBL] [Abstract][Full Text] [Related]
13. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
Macleod K; Mullen P; Sewell J; Rabiasz G; Lawrie S; Miller E; Smyth JF; Langdon SP
Cancer Res; 2005 Aug; 65(15):6789-800. PubMed ID: 16061661
[TBL] [Abstract][Full Text] [Related]
14. Dual apoptotic effect of Xrel3 c-Rel/NF-kappaB homolog in human cervical cancer cells.
Shehata M; Shehata M; Shehata F; Pater A
Cell Biol Int; 2004; 28(12):895-904. PubMed ID: 15566959
[TBL] [Abstract][Full Text] [Related]
15. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects.
Rocha A; Azevedo I; Soares R
J Cell Biochem; 2008 Feb; 103(2):607-14. PubMed ID: 17614352
[TBL] [Abstract][Full Text] [Related]
16. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
Campbell JS; Johnson MM; Bauer RL; Hudkins KL; Gilbertson DG; Riehle KJ; Yeh MM; Alpers CE; Fausto N
Differentiation; 2007 Nov; 75(9):843-52. PubMed ID: 17999742
[TBL] [Abstract][Full Text] [Related]
17. Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines.
Tanabe M; Izumi H; Ise T; Higuchi S; Yamori T; Yasumoto K; Kohno K
Cancer Res; 2003 Dec; 63(24):8592-5. PubMed ID: 14695168
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance.
Rudin CM; Yang Z; Schumaker LM; VanderWeele DJ; Newkirk K; Egorin MJ; Zuhowski EG; Cullen KJ
Cancer Res; 2003 Jan; 63(2):312-8. PubMed ID: 12543781
[TBL] [Abstract][Full Text] [Related]
19. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional activation of the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte growth factor) is mediated through AP-1.
Seol DW; Chen Q; Zarnegar R
Oncogene; 2000 Feb; 19(9):1132-7. PubMed ID: 10713700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]